Compare · BDMD vs DXCM
BDMD vs DXCM
Side-by-side comparison of Baird Medical Investment Holdings Ltd (BDMD) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDMD and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM carries a market cap of $40.07B.
- Over the past year, BDMD is down 67.8% and DXCM is down 13.5% - DXCM leads by 54.3 points.
- BDMD has been more active in the news (6 items in the past 4 weeks vs 4 for DXCM).
- DXCM has more recent analyst coverage (25 ratings vs 0 for BDMD).
- Company
- Baird Medical Investment Holdings Ltd
- DexCom Inc.
- Price
- $1.85+8.19%
- $61.55-1.84%
- Market cap
- -
- $40.07B
- 1M return
- -15.91%
- -7.89%
- 1Y return
- -67.83%
- -13.51%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 6
- 4
- Recent ratings
- 0
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest BDMD
- SEC Form 20-F filed by Baird Medical Investment Holdings Ltd
- SEC Form 3 filed by new insider Xu Lijian
- SEC Form 3 filed by new insider Qiu Quan
- SEC Form 3 filed by new insider Lu Rongjian
- SEC Form 3 filed by new insider Bilciu-Wolfson Gabrielle
- SEC Form 3 filed by new insider Li Jie Clara
- SEC Form 3 filed by new insider Ragan Joseph Douglas Iii
- SEC Form 3 filed by new insider Hou Wei
- SEC Form 3 filed by new insider Wu Haimei
- Baird Medical Advances Clinical Education with Expert-Led Workshops in Indonesia
Latest DXCM
- SEC Form 4 filed by Brown Michael Jon
- SEC Form DEFA14A filed by DexCom Inc.
- SEC Form DEF 14A filed by DexCom Inc.
- SEC Form 144 filed by DexCom Inc.
- Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time
- Amendment: SEC Form SCHEDULE 13G/A filed by DexCom Inc.
- Dexcom upgraded by Evercore ISI with a new price target
- SEC Form 4 filed by Brown Michael Jon
- Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026
- EVP, Chief Financal Officer Sylvain Jereme M was granted 48,774 shares and covered exercise/tax liability with 18,950 shares, increasing direct ownership by 24% to 153,292 units (SEC Form 4)